Drug discovery: Controlling protein SUMOylation
October 18th, 2017 by John S Schneekloth Jr
Drug discovery: Controlling protein SUMOylation
Nature Chemical Biology, Published online: 18 October 2017; doi:10.1038/nchembio.2496
A potent and selective inhibitor of protein SUMOylation, a ubiquitin-like post-translational modification, has been developed, shedding light on the potential for developing new classes of anticancer therapeutics.
Ubiquitin biology: Unraveling the chain
October 18th, 2017 by Grant Miura
Ubiquitin biology: Unraveling the chain
Nature Chemical Biology, Published online: 18 October 2017; doi:10.1038/nchembio.2508
Hop to It
October 13th, 2017 by Jillian L. Dempsey and Matthew R. Hartings
Fluorotryptophan Incorporation Modulates the Structure and Stability of Transthyretin in a Site-Specific Manner
September 28th, 2017 by Xun Sun, H. Jane Dyson and Peter E. Wright
Transfer Hydrogenation Catalyzed by Organometallic Complexes Using NADH as a Reductant in a Biochemical Context
September 27th, 2017 by Yasunori Okamoto and Thomas R. Ward
Cation−π Lights Up “Halo”
September 20th, 2017 by Jianmin Gao
Bioorthogonal chemistry: Click on, click off
September 19th, 2017 by Caitlin Deane
Nature Chemical Biology 13, 1057 (2017). doi:10.1038/nchembio.2482
Author: Caitlin Deane
Developmental signaling: Peaking early
September 19th, 2017 by Grant Miura
Nature Chemical Biology 13, 1057 (2017). doi:10.1038/nchembio.2484
Author: Grant Miura
Target class drug discovery
September 19th, 2017 by Kimberly D Barnash
Nature Chemical Biology 13, 1053 (2017). doi:10.1038/nchembio.2473
Authors: Kimberly D Barnash, Lindsey I James & Stephen V Frye
Selection of molecular targets based on disease understanding is a dominant paradigm in drug discovery. We argue that a focus on classes of targets with central roles in biology provides a complimentary approach that has higher quality outcomes in early discovery efforts.
Genome mining: Digging the tunnel for chemical space
September 19th, 2017 by Ha An Nguyen
Nature Chemical Biology 13, 1061 (2017). doi:10.1038/nchembio.2480
Authors: Ha An Nguyen & Christine M Dunham
Genome mining reveals a new ribosomally synthesized and post-translationally modified peptide (RiPP) from Klebsiella pneumoniae. This new antibiotic inhibits bacterial ribosomes by obstructing the peptide exit tunnel, and its modular nature presents a unique opportunity for future engineering of antibacterial drugs.